Avaí Bio, Inc. develops cell-based therapies centered on genetically modified cell lines, protective encapsulation technologies and joint venture or licensing structures. The company, formerly Avant Technologies Inc., uses the AVAI ticker and has described a biotechnology focus spanning diabetes, age-related disorders and anti-aging applications.
Recurring developments include the Insulinova diabetes program, which pairs insulin-producing or regulating cells with encapsulation technology, and the Klothonova α-Klotho program, which uses encapsulated cells designed to produce the longevity protein α-Klotho. Company updates also cover GMP manufacturing steps such as master cell bank production, research presentations, partner collaborations and the completed corporate name change to Avaí Bio.
Avant Technologies (OTCQB: AVAI) is presenting at the 15th EPITA Symposium in Igls, Austria, Jan 25-27, 2026, to evaluate advanced cells for potential use in a diabetes therapy.
The company said its representative, Dr. Eva Maria Lilli Brandtner, is assessing cells for combination with Avant's Cell-in-a-Box® microencapsulation platform, developed with SGAustria, which aims to protect transplanted insulin-producing cells without systemic immunosuppression.
The announcement emphasizes immunosuppression-free cell therapy approaches and Avant's goal to contribute to beta cell replacement for type 1 and insulin-dependent type 2 diabetes patients.
Avant Technologies (OTCQB: AVAI) announced a joint venture and license agreement with SGAustria to combine genetically modified insulin-producing cells with SGAustria's encapsulation technology.
The partners will form Insulinova, Inc. in the U.S. to facilitate and conduct clinical trials aimed at delivering long-term insulin production without immunosuppression using encapsulation like Cell-in-a-Box®.
The release highlights prior preclinical and clinical evidence for encapsulated beta cells and notes global diabetes prevalence estimates and forward-looking risks including development and financing.
Avant Technologies (OTCQB: AVAI) and Austrianova highlight a Mayo Clinic study linking low α-Klotho levels to arterial stiffness, vascular calcification and reduced survival in a 148‑patient cohort.
Avant and Austrianova’s joint venture, Klothonova, is developing an encapsulated, genetically modified cell therapy intended to sustainably restore circulating α-Klotho using Austrianova’s clinically validated Cell-in-a-Box® encapsulation platform.
The Mayo authors reported that low α-Klotho is independently associated with higher mortality and called for further research to clarify mechanisms and targeted treatments.
Pony.ai announced plans to enter Singapore with partner ComfortDelGro to deploy autonomous mobility services in the Punggol district, targeting fixed routes and an initial launch "in the coming months" pending regulatory approval.
The rollout follows a July 2024 MoU and a March 2025 pilot in Guangzhou. Pony.ai highlighted commercial Robotaxi operations in four tier‑1 Chinese cities covering >2,000 km2, 50 million km of autonomous driving mileage, a 136% YoY increase in registered users in Q2, and a user satisfaction rating above 4.8/5.
Avant Technologies (OTCQB: AVAI) and Singapore biotechnology company SGAustria announced a Joint Venture and License Agreement to develop a cell‑based diabetes therapy using stem cell differentiation and SGAustria’s encapsulation platform.
The partners will pursue a Research Collaboration Agreement (RCA), form a U.S. company named Insulinova, Inc. to facilitate clinical trials, and Avant will provide initial funding over the next eight months. SGAustria’s encapsulation technology is described as clinically proven and supported by over 50 peer‑reviewed publications and GMP manufacturing capabilities. The JV aims to enable a potential Phase 1 clinical trial in the United States or equivalent territory.
Avant Technologies (OTCQB: AVAI) and Austrianova launched joint venture Klothonova on Oct 21, 2025 to develop cell‑based therapies that overexpress the longevity protein Klotho.
R&D proof‑of‑concept produced genetically modified human cells that overproduce Klotho and, when encapsulated in Austrianova’s Cell‑in‑Box, produced similar protein levels to non‑encapsulated cells. The JV is equally owned and will advance a GMP‑grade human cell clone toward preclinical and clinical studies; Austrianova is requalifying its ISO9001:2015 GMP isolator and preparing required documentation. The JV cites a cell therapy market projection of about $44 billion.
Avant Technologies (OTCQB: AVAI) announced a strategic shift towards partnership-driven biotechnology development through joint ventures and licensing agreements. The company is focusing on advancing treatments for chronic and age-related conditions including diabetes, Alzheimer's, heart disease, cancer, and kidney disease.
The company's strategy involves collaborating with biotech firms specializing in genetically modified cell lines and partnering with a global cell-encapsulation technology company. Their first joint venture with Ainnova Tech incorporates Vision AI for non-invasive disease detection, while their latest venture focuses on developing cell line therapy for Klotho protein production, crucial for aging and disease processes.
Avant Technologies (OTCQB: AVAI) has issued a retraction of its September 24, 2025 press release regarding a purported Joint Venture and License Agreement with Art-Islets Pte. Ltd. and Austrianova. The company clarified that no binding agreement has been executed between the parties at this time.
The company acknowledged that the previous announcement contained statements issued in error and emphasized that any descriptions of collaborative activities, technology contributions, or anticipated clinical development milestones from the retracted release should not be relied upon. Avant Technologies expressed regret for any confusion caused and reaffirmed its commitment to providing accurate information to stakeholders.
Avant Technologies (OTCQB: AVAI) has formed a strategic Joint Venture with Art-Islets and Austrianova to develop innovative diabetes treatments using encapsulated stem cells. The collaboration combines Art-Islets' stem cell differentiation expertise with Austrianova's cell-encapsulation technology to create therapies for type 1 and insulin-dependent type 2 diabetes patients.
The partnership includes exclusive licensing agreements and plans for a potential U.S.-based entity to support clinical trials. Avant will provide initial funding over eight months to achieve the first three milestones, with additional funding planned to advance toward Phase 1 clinical trials. Art-Islets contributes its proprietary differentiation system for transforming ESCs into insulin-producing cells, while Austrianova brings its GMP-grade manufacturing expertise backed by over 50 peer-reviewed publications.
Avant Technologies (OTCQB: AVAI) and Austrianova have formed a joint venture called Klothonova, Inc. to develop cell-based therapies using encapsulated Klotho-producing cells. The 50/50 partnership combines Austrianova's proprietary cell-encapsulation technology and expertise with Avant's capital and resources.
The venture aims to develop treatments for Alzheimer's disease, heart disease, cancer, kidney disease, and age-related conditions. Austrianova brings significant expertise backed by over 50 peer-reviewed publications and global partnerships, while focusing on the therapeutic properties of Klotho, an 'anti-aging' protein discovered in 1997 that plays a crucial role in modulating aging and various physiological functions.